Download the Complete Report Here Beyond Oil Ltd. (BOIL/BEOLF) Record Revenue and U.S. Direct-Sales Buildout Support Scaling Phase; Enterprise Rollouts and Margin Recovery Shape 2H Setup Key Takeaways: 2Q26 revenue of $1.40 million increased 28% y/y and 11% sequentially, lifting first-half revenue 26% to $2.65 million. S. commercial infrastructure is increasingly established, with 100+ validated […] The post Beyond Oil: Record Revenue & U.S. Direct-Sales Expansion Fuel Scaling Phase – Quarterly

Ingredion’s Q2 results were met favorably by the market, driven by ongoing momentum in its Texture & Healthful Solutions segment. Management highlighted nine consecutive quarters of volume growth in this area, supported by customer demand for clean-label, health-forward ingredients and new product launches. Operational challenges at the Argo facility and softer demand in Food & Industrial Ingredients U.S./Canada tempered results, but sequential production improvements at Argo and robust executio

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how ingredients, flavors & fragrances stocks fared in Q2, starting with Ingredion (NYSE:INGR).

Tate & Lyle acquisition and Argo recovery amid tapioca cost pressures.

AgTech and food innovation reshape agriculture and nutrition, putting ADM, DAR and BG firmly in focus.

What the fresh guidance means for Ingredion stock Ingredion (INGR) has put updated numbers on the table. The company reaffirmed its full year 2026 earnings guidance and set expectations for modest net sales growth in the third quarter. This fresh guidance arrives alongside second quarter 2026 results, a completed buyback tranche, and progress on the proposed Tate & Lyle acquisition. Together, these developments give investors several new data points to weigh. See our latest analysis for...

ADM is benefiting from stronger biofuels economics and crushing margins while capacity investments support additional growth.

Archer Daniels raises its 2026 earnings outlook after a strong Q2, as crushing, ethanol and Nutrition gains fuel profit growth while execution risks remain.

Ingredion beats Q2 estimates as 7% Texture & Healthful Solutions volume growth and FX gains offset Argo issues and higher costs.

Ingredion (NYSE:INGR) reported second-quarter 2026 results that were in line with its expectations, as continued growth in Texture & Healthful Solutions offset operational and macroeconomic pressures in other parts of the portfolio. Second-quarter net sales increased 1% year over year to $1.85

Moby summary of Ingredion Incorporated's Q2 2026 earnings call

Texture and Healthful Solutions delivers record performance while Argo facility recovery and Tate & Lyle acquisition shape the company's outlook.

Ingredion (INGR) delivered earnings and revenue surprises of +3.30% and +2.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Food ingredient solutions provider Ingredion (NYSE:INGR) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.85 billion. Its non-GAAP profit of $2.82 per share was 3.6% above analysts’ consensus estimates.

Ingredion's proposed $5 billion Tate & Lyle deal could expand its specialty platform and global reach, but approvals and integration risks remain.

Ingredion's cheap valuation and growing specialty business support the bull case, but Argo execution risks and weaker guidance argue for patience.

Food ingredient solutions provider Ingredion (NYSE:INGR) will be reporting earnings this Tuesday before market open. Here’s what to expect.

The full-year range went up, but one of four segments was guided lower, and most of the second half now rests on the stretch that management flags for the most uncertainty.

Kraft Heinz (KHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ingredion (INGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tate & Lyle’s updated fair value estimate has shifted from £4.84 to £5.35, placing current analyst work more clearly in the mid £5 range that readers have seen referenced around recent price targets. That adjustment sits alongside commentary highlighting how the Ingredion offer and closely grouped targets between £5.47 and £5.95 are reshaping the risk and reward story, with several analysts moving to more neutral ratings. Keep reading to see how these numbers fit together and how to track the...